Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study

References

• Adler MW, Rogers TJ. 2005. Are chemokines the third major system in the brain? J Leukocyte Biol 78(6):1204–1209.
   PubMedGoogle Scholar
• APA. 1994. Diagnostic and statistical manual of mental disorders. 4th Washington, DC: American Psychiatric Association.
   Google Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162(3):441–449.
   PubMedGoogle Scholar
• Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, . 2008. N-Acetyl cysteine as a glutathione precursor for schizophrenia—A double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64:361–368.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya BJ, Banisadr G, Jung H, Ren D, Cronshaw DG, Zou Y, Miller RJ. 2008. The chemokine stromal cell-derived factor-1 regulates GABAergic inputs to neural progenitors in the postnatal dentate gyrus. J Neurosci 28(26):6720–6730.
   PubMed Web of Science ®Google Scholar
• Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. 2006. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404.
   PubMed Web of Science ®Google Scholar
• Carrizo E, Fernáxgndez V, Quintero J, Connell L, Rodríguez Z, Mosquera M, . 2008. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 103(1–3):83–93.
   PubMedGoogle Scholar
• de Jong EK, Vinet J, Stanulovic VS, Meijer M, Wesseling E, Sjollema K, . 2008. Expression, transport, and axonal sorting of neuronal CCL21 in large dense-core vesicles. FASEB J 22(12):4136–4145.
   PubMedGoogle Scholar
• de Jonge HJ, Fehrmann RS, de Bont ES, Hofstra RM, Gerbens F, Kamps WA, . 2007. Evidence based selection of housekeeping genes. PLoS ONE 2(9):e898.
   Google Scholar
• Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. 2006. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immunol 20(6):532–545.
   PubMed Web of Science ®Google Scholar
• Falkai P, Honer WG, David S, Bogerts B, Majtenyi C, Bayer TA. 1999. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol Appl Neurobiol 25(1):48–53.
   PubMedGoogle Scholar
• Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. 2010. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol [Epub ahead of print, 16 July, 1–8].
   PubMedGoogle Scholar
• Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, . 2010. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98(8):4746–4751.
   Google Scholar
• Hazlett EA, Buchsbaum MS, Haznedar MM, Newmark R, Goldstein KE, Zelmanova Y, . 2008. Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophrenia Res 101(1–3):111–123.
   PubMedGoogle Scholar
• Jahn T, Mussgay L. 1989. Die statistische Kontrolle möglicher Medikamenteneinflüsse in experimentalpsychologischen Schizophreniestudien: ein Vorschlag zur Berechnung von Chlorpromazinäquivalenten. Zeitschr Klin Psychol 18:257–267.
   Google Scholar
• Johnson RD, Oliver PL, Davies KE. 2008. SNARE proteins and schizophrenia: linking synaptic and neurodevelopmental hypotheses. Acta Biochim Pol 55(4):619–628.
   PubMedGoogle Scholar
• Lai AY, Swayze RD, El-Husseini A, Song C. 2006. Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons. J Neuroimmunol 175(1–2):97–106.
   PubMedGoogle Scholar
• Leucht S, Burkard T, Henderson JH, Maj M, Sartorius N. 2007. Physical illness and schizophrenia. A review of the evidence. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press.
   Google Scholar
• Li Y, Liu L, Barger SW, Griffin WS. 2003. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23(5):1605–1611.
   PubMedGoogle Scholar
• Maranto J, Rappaport J, Datta PK. 2008. Regulation of complement component C3 in astrocytes by IL-1beta and morphine. J Neuroimm Pharmacol 3(1):43–51.
   PubMedGoogle Scholar
• Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R, . 2009. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol Psychiatry 14(12):1083–1094.
   PubMedGoogle Scholar
• Mayilyan KR, Weinberger DR, Sim RB. 2008. The complement system in schizophrenia. Drug News Perspect 21(4):200–210.
   PubMedGoogle Scholar
• McLachlan JL, Smith AJ, Bujalska IJ, Cooper PR. 2005. Gene expression profiling of pulpal tissue reveals the molecular complexity of dental caries. Biochim Biophys Acta 1741(3):271–281.
   PubMedGoogle Scholar
• Meves H. 2006. The action of prostaglandins on ion channels. Curr Neuropharmacol 4(1):41–57.
   PubMedGoogle Scholar
• Nikkilä HV, Ahokas A, Wahlbeck K, Rimón R, Andersson LC. 2002. Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation. Neuropsychobiology 46(4):169–172.
   PubMedGoogle Scholar
• Oliva P, Berrino L, de Novellis V, Palazzo E, Marabese I, Siniscalco D, . 2006. Role of periaqueductal grey prostaglandin receptors in formalin-induced hyperalgesia. Eur J Pharmacol 530(1–2):40–47.
   PubMedGoogle Scholar
• Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998–1007.
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63(8):801–808.
   PubMed Web of Science ®Google Scholar
• Puma C, Danik M, Quirion R, Ramon F, Williams S. 2001. The chemokine interleukin-8 acutely reduces Ca(2+) currents in identified cholinergic septal neurons expressing CXCR1 and CXCR2 receptor mRNAs. J Neurochem 78(5):960–971.
   PubMedGoogle Scholar
• Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. 2009. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 33(7):1178–1183.
   PubMedGoogle Scholar
• Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. 2007. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46.
   PubMedGoogle Scholar
• Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, Falkai P. 2005. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis 1(2):171–177.
   Google Scholar
• Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M . 2006. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7:3.
   PubMed Web of Science ®Google Scholar
• Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, . 2008. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Prot Res 7(10):4266–4277.
   PubMedGoogle Scholar
• Serantes R, Arnalich F, Figueroa M, Salinas M, Andrés-Mateos E, Codoceo R, . 2006. Interleukin-1beta enhances GABAA receptor cell-surface expression by a phosphatidylinositol 3-kinase/Akt pathway: relevance to sepsis-associated encephalopathy. J Biol Chem 281(21):14632–14643.
   PubMedGoogle Scholar
• Shibuya I, Setiadji SV, Ibrahim N, Harayama N, Maruyama T, Ueta Y, Yamashita H. 2002. Involvement of postsynaptic EP4 and presynaptic EP3 receptors in actions of prostaglandin E2 in rat supraoptic neurones. J Neuroendocrinol 14(1):64–67.
   PubMedGoogle Scholar
• Smalla KH, Mikhaylova M, Sahin J, Bernstein HG, Bogerts B, Schmitt A . 2008. A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol Psychiatry 13(9):878–896.
   PubMedGoogle Scholar
• Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, . 2009. Common variants conferring risk of schizophrenia. Nature 460(7256):744–747.
   PubMedGoogle Scholar
• Stephan KE, Baldeweg T, Friston KJ. 2006. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 59(10):929–939.
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, . 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Takuwa Y, Takuwa N, Sugimoto N. 2002. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem 131(6):767–771.
   PubMedGoogle Scholar
• Tang C, Sula MJ, Bohnet S, Rehman A, Taishi P, Krueger JM. 2005. Interleukin-1beta induces CREB-binding protein (CBP) mRNA in brain and the sequencing of rat CBP. Brain Res Mol Brain Res 137(1–2):213–222.
   PubMedGoogle Scholar
• Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M. 2000. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 12(7):1015–1023.
   PubMedGoogle Scholar
• Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RESEARCH0034.
   PubMedGoogle Scholar
• Tretter F, Gebicke-Haerter PJ, Mendoza ER, Winterer G, 2010. Systems biology in psychiatric research. From high-throughput data to mathematical modeling. Weinheim, Germany: Wiley-VCH. ISBN: 978-3-527-32503-0.
   Google Scholar
• Viviani B, Gardoni F, Bartesaghi S, Corsini E, Facchi A, Galli CL, . 2006. Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J Biol Chem 281(40):30212–30222.
   PubMedGoogle Scholar
• Wenig L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. 2006. Rosetta error model for gene expression analysis. Bioinformatics 22(9):1111–1121.
   PubMedGoogle Scholar
• Xian X, Liu T, Yu J, Wang Y, Miao Y, Zhang J, . 2009. Presynaptic defects underlying impaired learning and memory function in lipoprotein lipase-deficient mice. J Neurosci 29(14):4681–4685.
   PubMedGoogle Scholar
• Yang ZW, Chengappa KN, Shurin G, Brar JS, Rabin BS, Gubbi AV, Ganguli R. 1994. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psych Med 24(2):449–455.
   Google Scholar
• Yao JK, Reddy RD. 2002. Membrane pathology in schizophrenia: implication for arachidonic acid signaling. Sci World J 2:1922–36.
   Google Scholar
• Zhang RX, Liu B, Li A, Wang L, Ren K, Qiao JT . 2008. Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience 154(4):1533–1538.
   PubMedGoogle Scholar
• Zhou C, Ye HH, Wang SQ, Chai Z. 2006. Interleukin-1beta regulation of N-type Ca2+ channels in cortical neurons. Neurosci Lett 403(1–2):181–185.
   PubMedGoogle Scholar
• Zhu P, Genc A, Zhang X, Zhang J, Bazan NG, Chen C. 2005. Heterogeneous expression and regulation of hippocampal prostaglandin E2 receptors. J Neurosci Res 81(6):817–826.
   PubMedGoogle Scholar